Literature DB >> 25018118

The use of bedaquiline in regimens to treat drug-resistant and drug-susceptible tuberculosis: a perspective from tuberculosis-affected communities.

Laia Ruiz Mingote1, Dorothy Namutamba1, Francis Apina1, Nomampondo Barnabas1, Carmen Contreras1, Taharqa Elnour1, Mike Watson Frick2, Cynthia Lee1, Barbara Seaworth1, Debra Shelly1, Natalie Skipper1, Ezio Tavora dos Santos Filho1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2014        PMID： 25018118     DOI： 10.1016/S0140-6736(14)60523-7

Source DB:  PubMed          Journal:  Lancet        ISSN： 0140-6736            Impact factor:   79.321


× No keyword cloud information.
  4 in total

1.  Verapamil increases the bactericidal activity of bedaquiline against Mycobacterium tuberculosis in a mouse model.

Authors:  Shashank Gupta; Sandeep Tyagi; William R Bishai
Journal:  Antimicrob Agents Chemother       Date:  2014-10-20       Impact factor: 5.191

2.  Are we moving towards a new definition of essential medicines?

Authors:  S Manikandan
Journal:  J Pharmacol Pharmacother       Date:  2015 Jul-Sep

3.  Tradeoffs in Introduction Policies for the Anti-Tuberculosis Drug Bedaquiline: A Model-Based Analysis.

Authors:  Amber Kunkel; Frank G Cobelens; Ted Cohen
Journal:  PLoS Med       Date:  2016-10-11       Impact factor: 11.069

Review 4.  Re-Understanding the Mechanisms of Action of the Anti-Mycobacterial Drug Bedaquiline.

Authors:  Jickky Palmae Sarathy; Gerhard Gruber; Thomas Dick
Journal:  Antibiotics (Basel)       Date:  2019-12-11
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.